2003
DOI: 10.1016/s1062-1458(02)00991-1
|View full text |Cite
|
Sign up to set email alerts
|

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

9
161
3
9

Year Published

2003
2003
2012
2012

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 130 publications
(182 citation statements)
references
References 0 publications
9
161
3
9
Order By: Relevance
“…8 An observational study conducted in the Tennessee Medicaid population found that rofecoxib at dosages Ͼ25 mg/d was associated with a nearly 2-fold increased risk of AMI compared with nonuse of any NSAID. 9 Our findings differ from the pooled analyses of rofecoxib randomized controlled trials, which showed no significant increase in cardiovascular events compared with non-naproxen NSAIDs. 6,7 In addition, a recently published observational analysis from Ontario also found no increased risk of AMI associated with any dosage of rofecoxib.…”
Section: Discussioncontrasting
confidence: 99%
See 2 more Smart Citations
“…8 An observational study conducted in the Tennessee Medicaid population found that rofecoxib at dosages Ͼ25 mg/d was associated with a nearly 2-fold increased risk of AMI compared with nonuse of any NSAID. 9 Our findings differ from the pooled analyses of rofecoxib randomized controlled trials, which showed no significant increase in cardiovascular events compared with non-naproxen NSAIDs. 6,7 In addition, a recently published observational analysis from Ontario also found no increased risk of AMI associated with any dosage of rofecoxib.…”
Section: Discussioncontrasting
confidence: 99%
“…On the basis of previous findings that first-time users may be at the highest risk for cardiovascular events associated with coxibs, 9 we constructed conditional regression models that considered persons exposed only if their use on the index date was their first time using a coxib. We examined the relationship between AMI and the duration of exposure to coxibs in this group of users.…”
Section: Solomon Et Al Cox-2 Inhibitors and Acute Myocardial Infarctimentioning
confidence: 99%
See 1 more Smart Citation
“…In fact, we observed a significant resistance of HUVE cells to the pSUPER.retro viral infection in comparison with different types of human cancer cells, either CRC cells (HT29 and HCA7) and cervix carcinoma cells (HeLa). This observation indicates that endothelial cells are refractory to retroviral infection and suggests that this kind of virus-based approach might not affect the physiological prostaglandins production in vascular tissues, avoiding some of the well-known side effects coming from therapies based on selective COX-2 inhibitors (coxibs) (Ray et al, 2002;Fitzegerald, 2004;Horton, 2004;Mamdani et al, 2004;Oberholzer and Inamdar, 2004;Mitchell and Warner, 2005).…”
Section: Discussionmentioning
confidence: 99%
“…These side effects appear to be related to the drugs' inhibition of COX-1 because constitutive expression of COX-2 in normal gastric mucosal tissue is low or absent [9] . However, COX-2 inhibitors may increase the risk of cardiovascular complications, such as heart attack or stroke, especially if they are used for a prolonged time [10] . In this study, we focused on finding NSAIDs that target the nuclear factor-kappa B (NF-κB) signaling pathway, but not COXs.…”
Section: Introductionmentioning
confidence: 99%